Search clinical trials for: 5 Azacytidine

Total 8270 results

M.D. Anderson Cancer Center
Celgene Corporation

Completed

Phase II 5-Azacytidine Plus VPA Plus ATRA

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation (M1) | Adult Acute... and other conditions

United States
TetraLogic Pharmaceuticals

Completed

Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy

Myelodysplastic Syndrome

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Completed

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells

United States
HealthCore-NERI
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia

Thalassemia

United States, Canada
Technische Universität Dresden

Completed

Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)

Myeloid Leukemia | Myelodysplastic Syndrome

Germany
OHSU Knight Cancer Institute
Oregon Health and Science University; Oryzon Genomics S.A.

Not yet recruiting

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndrome/Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Celgene

Completed

Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)

Leukemia | AML | MDS

United States
M.D. Anderson Cancer Center
Celgene

Completed

5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Leukemia

United States
Zhujiang Hospital

Recruiting

Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients

Leukemia, Myeloid, Acute

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | IDH2 Gene Mutation | Acute Bilineal Leukemia | Acute Biphenotypic Leukemia

United States
Università degli Studi di Brescia
University of Bologna; University of Udine; University of Genova; University of... and other collaborators

Completed

5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs) (MDSAZA0706)

Myelodysplastic Syndrome

Italy
Grupo Cooperativo de Hemopatías Malignas

Withdrawn

Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Mexico
National Cancer Institute (NCI)

Terminated

Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia and other conditions

Canada
Yale University

Completed

Window Trial 5-aza in HNSCC, T-tare

Head and Neck Squamous Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

FLT3 Gene Mutation Negative | FLT3 Internal Tandem Duplication Positive | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic...

United States
Washington University School of Medicine

Completed

A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Assistance Publique Hopitaux De Marseille

Unknown

Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine

Myelodysplastic Syndromes | Myeloid Leukemia

France
Shenzhen Second People's Hospital

Recruiting

Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy

Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia

China
Heinrich-Heine University, Duesseldorf

Completed

Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Germany
Nanexa AB
Uppsala University

Completed

Pharmacokinetics, Tolerability and Safety of NEX-18a

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)

Sweden
Tel-Aviv Sourasky Medical Center

Unknown

Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome (ViLen 001)

Myelodysplastic Syndrome

Israel
Columbia University
Celgene

Terminated

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

Lymphoma | Hodgkin Lymphoma | Lymphoid Malignancies | Non-hodgkin Lymphoma

United States
Washington University School of Medicine

Completed

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) (MDS)

Myelodysplastic Syndromes

United States
M.D. Anderson Cancer Center
Yukiguni Maitake Company Ltd.

Terminated

Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide

Advanced Cancers

United States
M.D. Anderson Cancer Center

Completed

Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients

Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Ruijin Hospital
The First Affiliated Hospital of Anhui Medical University; The First Affiliated... and other collaborators

Recruiting

Genotype-guided Treatment in Newly Diagnosed PTCL (THEORY)

Peripheral T Cell Lymphoma

China
Stanford University
Celgene Corporation

Completed

Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Adult Acute Myeloblastic Leukemia

United States
Memorial Sloan Kettering Cancer Center

Completed

Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

Myelodysplastic Syndromes (MDS) | Acute Myelogenous Leukemia (AML)

United States
University of Virginia

Recruiting

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Lymphoma, T-Cell

United States
SymBio Pharmaceuticals

Withdrawn

Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
Ascentage Pharma Group Inc.

Recruiting

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | AML | MDS | CMML | High-risk Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; Celgene Corporation

Completed

Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Leukemia

United States
University of Utah
Celgene

Completed

A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Active, not recruiting

Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

Myelodysplastic Syndromes

Italy
Stanford University
Celgene Corporation

Terminated

Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

Leukemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)

United States
Daiichi Sankyo, Inc.

Terminated

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Case Comprehensive Cancer Center

Completed

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma

United States
GlaxoSmithKline

Terminated

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Neoplasms

United States, Canada
University of Kansas Medical Center
Celgene Corporation

Terminated

Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma

United States
Federal University of Rio Grande do Sul

Completed

n-3 Fatty Acid Effects in T2DM After Acute High Intensity Exercise

Type2 Diabetes Mellitus

Brazil
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Suspended

Magrolimab in Combination With Azacitidine After Allogeneic HCTin Treating Patients With High-Risk AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
University Hospital Muenster
Celgene Corporation; Amgen

Completed

Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (AML-AZA)

Acute Myeloid Leukemia

Germany
Carlos Graux, MD, PhD
Celgene Corporation; Belgian Hematological Society

Completed

Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

Belgium
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome/Acute Myeloid Leukemia

United States
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC; Celgene

Completed

Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)

Lymphoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant

Leukemia

United States

Search clinical trials for: 5 Azacytidine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations